Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.

Bibliographic Details
Title: Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.
Authors: Mortimer, Joanne E., Bading, James R., Frankel, Paul H., Carroll, Mary I., Yuan, Yuan, Park, Jinha M., Tumyan, Lusine, Gidwaney, Nikita, Poku, Erasmus K., Shively, John E., Colcher, David M.
Source: Journal of Nuclear Medicine; Dec2021, Vol. 62 Issue 12, p1-15, 28p
Database: Complementary Index
More Details
ISSN:01615505
DOI:10.2967/jnumed.121.262940
Published in:Journal of Nuclear Medicine
Language:English